Datapoint: FDA Approves Coherus Lucentis Copy

The FDA last week approved Coherus BioSciences, Inc.’s Lucentis biosimilar, Cimerli, across all five of its indications. The anti-VEGF therapy will be interchangeable with Lucentis, a blockbuster for manufacturer Roche, and hold interchangeability exclusivity for 12 months. The first Lucentis biosimilar, Byooviz, was approved in September 2021, but for just three of Lucentis’s indications, including wet age-related macular degeneration (AMD). For the treatment of AMD, Lucentis holds covered or better status for 86% of all insured lives under the medical benefit, to Byooviz’s 68%.

SOURCE: MMIT Analytics, as of 8/8/22

0 Comments
© 2024 MMIT
Carina Belles

Carina Belles

Carina has been covering public-sector health care since 2018. As a data reporter for Radar on Medicare Advantage, she creates infographics and data stories on issues impacting Medicare, Medicaid and Part D. She also develops AIS Health Daily, a free daily newsletter that showcases AIS’s strong reporting across our four publications and parent company Norstella’s suite of market access and data solutions. Prior to joining the editorial team, she managed Medicare and Medicaid data for the Directory of Health Plans, AIS’s industry-standard health coverage database. She graduated from Ohio University with a B.S. in Journalism.

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today